Evaluation of Rhenium and Technetium-99m Complexes Bearing Quinazoline Derivatives as Potential EGFR Agents
Molecules · 2023
DOI: 10.3390/molecules28041786 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, 2023. Verfasst von Konstantina Makrypidi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Nuclear and Radiological Sciences and Technology, Energy & Safety, NCSR "Demokritos", 15310 Athens, Greece. Hauptthemen laut MEDLINE: Rhenium, Technetium. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Τhe Epidermal Growth Factor Receptor tyrosine kinase inhibitor (EGFR-TKI) 6-amino-4-[(3-bromophenyl) amino]quinazoline was derivatized with 6-bromohexanoyl-chloride and coupled with the tridentate chelating agents N-(2-pyridylmethyl) aminoethyl acetic acid (PAMA) and L(+)-cysteine bearing the donor atom set NNO and SNO, respectively. The rhenium precursors ReBr(CO)5 and fac-[NEt4]2[ReBr3(CO)3] were used for the preparation of the Re complexes fac-[Re(NNO)(CO)3] (5a) and fac-[Re(SNO)(CO)3] (7a) which were characterized by NMR and IR spectroscopies. Subsequently, the new potential EGFR inhibitors were labeled with the fac-[99mTc(CO)3]+ core in high yield and radiochemical purity (>90%) by ligand exchange reaction using the fac-[99mTc][Tc(OH2)3(CO)3]+ precursor. The radiolabeled complexes were characterized by comparative HPLC analysis with the analogous rhenium (Re) complexes as references. In vitro studies in the A431 cell lines showed that both ligands and Re complexes inhibit A431 cell growth. Complex 5a demonstrated the highest potency (IC50 = 8.85 ± 2.62 μM) and was further assessed for its capacity to inhibit EGFR autophosphorylation, presenting an IC50 value of 26.11 nM. Biodistribution studies of the 99mTc complexes in healthy mice showed high in vivo stability for both complexes and fast blood and soft tissue clearance with excretion occurring via the hepatobiliary system.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Nuclear and Radiological Sciences and Technology, Energy & Safety, NCSR "Demokritos", 15310 Athens, Greece.
- Institute of Biosciences & Applications, NCSR "Demokritos", 15310 Athens, Greece.
ORCID-Profile: Konstantina Makrypidi, Antonio Shegani, Aristeidis Chiotellis, Maria Pelecanou, Ioannis Pirmettis
Zitieren
APA
Makrypidi, K., Kiritsis, C., Roupa, I., Triantopoulou, S., Shegani, A., Paravatou-Petsotas, M., Chiotellis, A., Pelecanou, M., Papadopoulos, M., & Pirmettis, I. (2023). Evaluation of Rhenium and Technetium-99m Complexes Bearing Quinazoline Derivatives as Potential EGFR Agents. Molecules. https://doi.org/10.3390/molecules28041786
Vancouver
Makrypidi K, Kiritsis C, Roupa I, Triantopoulou S, Shegani A, Paravatou-Petsotas M, et al. Evaluation of Rhenium and Technetium-99m Complexes Bearing Quinazoline Derivatives as Potential EGFR Agents. Molecules. 2023. doi:10.3390/molecules28041786
BibTeX
@article{Makrypidi2023,
author = {Makrypidi, Konstantina and Kiritsis, Christos and Roupa, Ioanna and Triantopoulou, Sotiria and Shegani, Antonio and Paravatou-Petsotas, Maria and Chiotellis, Aristeidis and Pelecanou, Maria and Papadopoulos, Minas and Pirmettis, Ioannis},
title = {Evaluation of Rhenium and Technetium-99m Complexes Bearing Quinazoline Derivatives as Potential EGFR Agents},
journal = {Molecules},
year = {2023},
doi = {10.3390/molecules28041786}
}
EUVIMED